Publications

Abstract not provided.

Emerging infectious diseases present a profound threat to global health, economic development, and political stability, and therefore represent a significant national security concern for the United States. The increased prevalence of international travel and globalized trade further amplify the threat of infectious disease outbreaks of catastrophic effect. The key to containing and eradicating an outbreak before it goes global is rapid identification of index cases and initial clusters of affected individuals. This depends upon establishment of a biosurveillance network that effectively reaches infectious disease hotspots in even the most remote regions of the world and provides a network-integrated, location-appropriate diagnostic capability. At present, there are two critical needs which must be addressed in order to extend biosurveillance activities beyond centralized laboratory facilities: 1) A simple, reliable, and safe method for immediate stabilization of clinical specimens in the field; and 2) A flexible sample processing platform that enables in-field preparation of clinical specimens for rapid, on-site analysis using a variety of diagnostic assay platforms. These needs are not necessarily mutually exclusive; in fact, we propose that they are most efficiently addressed by a deployable sample processing platform that immediately stabilizes the information content of clinical specimens through transformation of the inherently unstable analytes of interest into stable equivalents that are appropriately formatted for downstream analysis. In order to address this problem, we have developed a sample processing pipeline and microfluidics-based platform modules enabling: 1) Extraction of total RNA from finger-stick quantities of human whole blood; and 2) Microscale synthesis of appropriately-formatted cDNA products that capture the information content of blood RNA in a stable form that supports pathogen detection and/or characterization via PCR and/or Second Generation Sequencing (SGS). Through this research we have discovered new, effective solutions for problems that thus far have hindered use of digital microfluidics (DMF) in biomedical applications. Our work reveals a clear path forward to fieldable, automated sample processing systems that will enable rapid, on-site identification of usual-suspect and novel pathogens in clinical specimens for improved biosurveillance.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Uncultivable microorganisms likely play significant roles in the ecology within the human body, with subtle but important implications for human health. Focusing on the oral microbiome, we are developing a processor for targeted isolation of individual microbial cells, facilitating whole-genome analysis without the need for isolation of pure cultures. The processor consists of three microfluidic modules: identification based on 16S rRNA fluorescence in situ hybridization (FISH), fluorescence-based sorting, and encapsulation of individual selected cells into small droplets for whole genome amplification. We present here a technique for performing microscale FISH and flow cytometry, as a prelude to single cell sorting.

Abstract not provided.

Abstract not provided.

Abstract not provided.

Bioweapons and emerging infectious diseases pose formidable and growing threats to our national security. Rapid advances in biotechnology and the increasing efficiency of global transportation networks virtually guarantee that the United States will face potentially devastating infectious disease outbreaks caused by novel ('unknown') pathogens either intentionally or accidentally introduced into the population. Unfortunately, our nation's biodefense and public health infrastructure is primarily designed to handle previously characterized ('known') pathogens. While modern DNA assays can identify known pathogens quickly, identifying unknown pathogens currently depends upon slow, classical microbiological methods of isolation and culture that can take weeks to produce actionable information. In many scenarios that delay would be costly, in terms of casualties and economic damage; indeed, it can mean the difference between a manageable public health incident and a full-blown epidemic. To close this gap in our nation's biodefense capability, we will develop, validate, and optimize a system to extract nucleic acids from unknown pathogens present in clinical samples drawn from infected patients. This system will extract nucleic acids from a clinical sample, amplify pathogen and specific host response nucleic acid sequences. These sequences will then be suitable for ultra-high-throughput sequencing (UHTS) carried out by a third party. The data generated from UHTS will then be processed through a new data assimilation and Bioinformatic analysis pipeline that will allow us to characterize an unknown pathogen in hours to days instead of weeks to months. Our methods will require no a priori knowledge of the pathogen, and no isolation or culturing; therefore it will circumvent many of the major roadblocks confronting a clinical microbiologist or virologist when presented with an unknown or engineered pathogen.

Abstract not provided.